Legend Biotech
Develops cell therapies for the treatment of cancer.
Company facts
- Founded
- 2014
- Employees
- 3,000
- Headquarters
- United States
- CEO
- Ying Huang, Ph.D.
- Type
- Public
- Listed
- NASDAQ: LEGN
- Subsidiaries
- Legend Biotech USA, Legend Biotech Ireland, Legend Biotech Belgium
About
Legend Biotech is a global, commercial-stage biotechnology company developing, manufacturing, and commercializing novel therapies. We explore and apply innovative technologies to deliver cutting-edge options for patients around the world. Founded in 2014, our mission is to find, create, and bring novel therapies to patients with life-threatening diseases. We began as an early-stage cell therapy company with a vision set by a group of pioneering scientists focusing on advancing antibody-based therapeutics. Our expertise in immunology and gene editing set the foundation for developing therapies, particularly in the field of Oncology. Over the years, our flagship therapy, CARVYKTI™, was recognized for its success in treating multiple myeloma, illustrating the impact of our innovative approach. We have also expanded our pipeline to include CAR-T, CAR-NK, CAR-γδ T, and non-gene-editing CAR technologies. Our research and clinical trials have been pivotal in establishing our position as a leader in the biotechnology industry, demonstrating our commitment to advancing health solutions for patients.